Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment

Supreeda Tambunlertchai; Sean M. Geary; Aliasger K. Salem

doi:10.3390/pharmaceutics14102076

Back

Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment

Journal article

Open access

Peer reviewed

Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment

Supreeda Tambunlertchai, Sean M. Geary and Aliasger K. Salem

Pharmaceutics, Vol.14(10), 2076

09/29/2022

DOI: 10.3390/pharmaceutics14102076

PMCID: PMC9611754

PMID: 36297510

Files and links (1)

url

https://doi.org/10.3390/pharmaceutics14102076View

Published (Version of record) Open Access

Abstract

Melanoma is the most lethal form of skin cancer and surgery remains the preferred and most effective treatment. Nevertheless, there are cases where surgery is not a viable method and alternative treatments are therefore adopted. One such treatment that has been tested is topical 5% imiquimod (IMQ) cream, which, although showing promise as a treatment for melanoma, has been found to have undesirable off-target effects. Resiquimod (RSQ) is an immunomodulatory molecule that can activate immune responses by binding to Toll-like receptors (TLR) 7 and 8 and may be more effective than IMQ in the context of melanoma treatment. RSQ can cross the stratum corneum (SC) easily without requiring pretreatment of the skin. In a gel formulation, RSQ has been studied as a monotherapy and adjuvant for melanoma treatment in pre-clinical studies and as an adjuvant in clinical settings. Although side effects of RSQ in gel formulation were also reported, they were never severe enough for the treatment to be suspended. In this review, we discuss the potential use of RSQ as an adjuvant for melanoma treatment.

adjuvant

imiquimod

melanoma

resiquimod

Review

topical

Details

Title: Subtitle: Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment
Creators: Supreeda Tambunlertchai - University of Iowa
Sean M. Geary - University of Iowa
Aliasger K. Salem - Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
Resource Type: Journal article
Publication Details: Pharmaceutics, Vol.14(10), 2076
DOI: 10.3390/pharmaceutics14102076
PMID: 36297510
PMCID: PMC9611754
NLM abbreviation: Pharmaceutics
ISSN: 1999-4923
eISSN: 1999-4923
Publisher: MDPI
Language: English
Date published: 09/29/2022
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
Record Identifier: 9984306927502771

Metrics

19 Record Views

16 Times Cited - Web of Science